CN1160582A - External-use composite containing cell growth factor - Google Patents
External-use composite containing cell growth factor Download PDFInfo
- Publication number
- CN1160582A CN1160582A CN 96114282 CN96114282A CN1160582A CN 1160582 A CN1160582 A CN 1160582A CN 96114282 CN96114282 CN 96114282 CN 96114282 A CN96114282 A CN 96114282A CN 1160582 A CN1160582 A CN 1160582A
- Authority
- CN
- China
- Prior art keywords
- growth factor
- compositions
- cell growth
- substrate
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003102 growth factor Substances 0.000 title claims abstract description 48
- 230000010261 cell growth Effects 0.000 title claims abstract description 44
- 239000002131 composite material Substances 0.000 title abstract 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 48
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 43
- 239000002502 liposome Substances 0.000 claims abstract description 31
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 23
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 23
- 239000003381 stabilizer Substances 0.000 claims abstract description 21
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 115
- 239000000499 gel Substances 0.000 claims description 55
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 39
- 239000000758 substrate Substances 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 32
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 32
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 32
- 238000002360 preparation method Methods 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 229920002674 hyaluronan Polymers 0.000 claims description 14
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 11
- 239000000080 wetting agent Substances 0.000 claims description 11
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 10
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- 102000013275 Somatomedins Human genes 0.000 claims description 10
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 10
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- 150000004804 polysaccharides Chemical class 0.000 claims description 10
- -1 CSSO3 Polymers 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 7
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 229960000633 dextran sulfate Drugs 0.000 claims description 7
- 229920000669 heparin Polymers 0.000 claims description 7
- 229960002897 heparin Drugs 0.000 claims description 7
- 239000001117 sulphuric acid Substances 0.000 claims description 7
- 235000011149 sulphuric acid Nutrition 0.000 claims description 7
- 229920002971 Heparan sulfate Polymers 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229940099552 hyaluronan Drugs 0.000 claims description 6
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 6
- 229940053128 nerve growth factor Drugs 0.000 claims description 6
- 238000010188 recombinant method Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- 241000206575 Chondrus crispus Species 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920000057 Mannan Polymers 0.000 claims description 3
- 229920003091 Methocel™ Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 3
- 235000003969 glutathione Nutrition 0.000 claims description 3
- 229960003180 glutathione Drugs 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 229920001206 natural gum Polymers 0.000 claims description 3
- 108010094020 polyglycine Proteins 0.000 claims description 3
- 229920000232 polyglycine polymer Polymers 0.000 claims description 3
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- 229940123457 Free radical scavenger Drugs 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 102400001368 Epidermal growth factor Human genes 0.000 claims 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims 1
- 229940058015 1,3-butylene glycol Drugs 0.000 claims 1
- 229920000045 Dermatan sulfate Polymers 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 235000019437 butane-1,3-diol Nutrition 0.000 claims 1
- 229940105329 carboxymethylcellulose Drugs 0.000 claims 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims 1
- 229940051593 dermatan sulfate Drugs 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229960002900 methylcellulose Drugs 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract description 21
- 239000000839 emulsion Substances 0.000 abstract description 20
- 230000004071 biological effect Effects 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 230000035699 permeability Effects 0.000 abstract description 3
- 239000000017 hydrogel Substances 0.000 abstract description 2
- 230000001012 protector Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 24
- 150000002632 lipids Chemical class 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 239000002537 cosmetic Substances 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 239000003995 emulsifying agent Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 150000003904 phospholipids Chemical class 0.000 description 7
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- 239000003223 protective agent Substances 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 150000004671 saturated fatty acids Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 241001597008 Nomeidae Species 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229940087168 alpha tocopherol Drugs 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003328 fibroblastic effect Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000007764 o/w emulsion Substances 0.000 description 3
- 206010033675 panniculitis Diseases 0.000 description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000004304 subcutaneous tissue Anatomy 0.000 description 3
- 229960000984 tocofersolan Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000004835 α-tocopherol Nutrition 0.000 description 3
- 239000002076 α-tocopherol Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 125000005250 alkyl acrylate group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920003086 cellulose ether Polymers 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 150000004668 long chain fatty acids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- JTHZUSWLNCPZLX-UHFFFAOYSA-N 6-fluoro-3-methyl-2h-indazole Chemical compound FC1=CC=C2C(C)=NNC2=C1 JTHZUSWLNCPZLX-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101100120045 Bos taurus FGF1 gene Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 241000533849 Gleditsia Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
- 108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical group CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000000184 acid digestion Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000011602 growth factor activity proteins Human genes 0.000 description 1
- 108040004165 growth factor activity proteins Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- PBOSTUDLECTMNL-UHFFFAOYSA-N lauryl acrylate Chemical compound CCCCCCCCCCCCOC(=O)C=C PBOSTUDLECTMNL-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- RVUARBOQHOGOTL-UHFFFAOYSA-N methyl 2-methylideneicosanoate Chemical compound CCCCCCCCCCCCCCCCCCC(=C)C(=O)OC RVUARBOQHOGOTL-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000008747 mitogenic response Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229930004090 phosphatidylinositide Natural products 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000003009 skin protective agent Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
Landscapes
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention provides external use composite containing cell growth factor, esp one containing fibroblast growth factor-2 and/or epidermal growth factor, and the composite features that it contains efficient protector and stabilizer for the protein of the said cell growth factor and that it may be in form of hydrogel, aqueous solution, emulsion or liposomes. The active component in the said composite may maintain maximal biological activity and infiltrate into skin to produce its biological effect. On the other hand, the said composite has also excellent skin feeling and remaining property as well as excellent moisture bearing property, permeability and absorption.
Description
The present invention relates to composition for external application, particularly relate to the composition for external application and the production method thereof of the different dosage form that contains cell growth factor.Composition for external application of the present invention has to normal or be subjected to ultraviolet light, and the skin histology of inflammation and/or wound infringement stably discharges the competent cell growth factor peptides, prevents the function of atrophoderma, shriveling with treatment scytitis and/or wound and performance.
As far back as period in time immemorial, the mankind just know and utilize natural plant sap, pigment and various colored mineral powder to make cosmetics.These cosmetics mainly are purpose with the beauty treatment, and some composition may be to the toxic effect of skin.After chemical industry rises and is constantly progressive, the cosmetics emulsifiable, that beauty treatment and skin care effect are arranged have progressively been invented based on hydro carbons, esters, alcohols chemical substance.Since mid-term in this century,, concern and pursuit have also been increased to beauty treatment and skin care along with the continuous improvement of rapid development of economy and people's material life.In recent decades, in some countries of comprising China, Japan and Korea S the many water of Chinese herbal medicine (comprising plant, animal and mineral origin) or cosmetics of alcohol extract of being added with have appearred particularly, these Chinese herbal medicine comprise but are not only limited to Radix Ginseng, Fructus Gleditsia, Radix Angelicae Sinensis, the Radix Angelicae Dahuricae, pollen, Semen Ginkgo, Aloe, Margarita powder etc. (for example referring to Chinese patent application 87150120,87105347,89100708,92109672,93104735,93102038, and the clear 60-23325 of Japanese Patent Application Laid-Open).After the seventies middle and late stage table of discovery skin growth factor (EGF) and fibroblast growth factor cell growth factor such as (FGF); also existing people attempts to add one or more independent cell growth stimulation peptides in conventional cosmetics, and expectation prepares so-called functional cosmetics and external skin protective agent with it as active component.
Polypeptide growth factor is the hormonelike regulator of cell proliferation and differentiation.From various tissues and cell, separated and identified many somatomedin, comprising epidermal growth factor, platelet-derived somatomedin, nerve growth factor, hematopoietic cell growth factor and fibroblast growth factor.
Fibroblast growth factor (FGF) is as BALB/c 3T3 fibroblast being had the factor of growth-promoting activity, isolating from the cattle pituitary tissue (D.Gospodarowicz, Nature 249:123,1974) at first.This molecule is to acid and responsive to temperature, and has high (alkalescence) isoelectric point, IP.Found from brain isolating mitogenic factor afterwards with isolating different from hypophysis cerebri before this, thereby have similar biologic activity based on them and be called acid and basic FGF (being aFGF and bFGF) with different isoelectric point, IPs.AFGF and bFGF are the members of relevant at least 8 kinds of structures, as to have heparin affinity molecule family, they can optionally excite the biologically of the many cell types that comprise mesoblastema and neuroderm cell, and these cells comprise endotheliocyte, smooth muscle cell, adrenal cortical cell, sarcoplast and osteoblast.Cattle bFGF has 154 amino acid whose polypeptide.People bFGF is different from cattle bFGF and is that its 121st amino acids is threonine (Thr) rather than serine (Ser), and the 137th amino acids is serine (Ser) rather than proline (Pro).This description hereinafter is referred to as FGF-2 with the human alkaline fibroblast growth factor analog of the disclosed FGF-2m of being called in cattle and human alkaline fibroblast growth factor and our patent application of awaiting the reply jointly (application number 96114279.0).
Except stimulating cellular growth, FGF also can stimulate the cell of many types in non-mitosis mode different reactions to take place, for example promote cell to injury migration (chemotactic factor activity), new angiogenesis, adjusting nerve degeneration and viability (neurotrophic activity), endocrine regulation function and stimulation or the (Baird such as inhibition specific cell protein expression, extracellular matrix generation and cell survival of promotion, A.and Bohler, P., Handbook of Exp.Pharmacol., 95 (1): 369-418,1990).The FGF preparation is used for that accelerating wound healing, nervous tissue are repaired to these character in order to use, the medicine of prevention and treatment brain and myocardial ischaemia (collateral blood vessels generation) is laid a good foundation.Moreover, only with regard to effect, be the mesoderm that subcutaneous tissue all derives from the embryo because the second layer of skin histology is dermal tissue and the 3rd layer, so skin histology is the main target site of FGF just to skin histology.Existing many research work confirm, FGF can promote the differentiation and the propagation of corium and subcutaneous tissue inner cell, the acceleration cell upgrades, more collagen fiber of justacrine and elastic fiber and substrate (Sprugel K.H., et al., Effect of growthfactor in vivo.l.cell ingrowth into porous supcutaneouschambers.Am.J.Pathol.129:601-613,1987), thus play the effect of delaying decrepitude of skin.Particularly, FGF can by " dose-effect effect " in other words " cascade amplification " promote the differentiation and the propagation of cell, it acts on than hormone more trickle (the Schweigere L.et al. of the influence of airframe systems, Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their owngrowth, Nature 325:257-259,1987).FGF is different from other hormonelike peptide class somatomedin and is that it mainly acts on the deep tissues and the cell of skin, and the aging basic reason of skin aging, shrinkage just of skin corium and subcutaneous tissue.
The growth factor polypeptide that epidermal growth factor (EGF is also referred to as urogastrone) is made up of 53 or 52 aminoacid.Found that EGF has short mitotic activity to the polytype cell that comprises epidermis and Interstitial cell and fibroblast, thereby can be used for accelerating wound healing and treat digestive tract ulcer (Knauer, D.J.et al., Relationship betweenepidermal growth factor receptor occupaney and mitogenic response, J.Biol.Chem.259 (9): 5623-5631,1984; Okeef, E.et al., Invest.Dermatol., 78:482-485,1982 and United States Patent (USP) 4,820,690).Topical application with regard to this somatomedin, disclose and used the EGF (β-urogastrone) that from urine, extracts to mix mutually with conventional cosmetic base, made the composition for external application or the cosmetics (seeing clear 61-15810 of Japanese patent application and Chinese patent application CN1063410A) of the multiple dosage form that comprises astringent, ointment, emulsion and lipstick as active component.
As everyone knows, the polypeptide growth factor that comprises epidermal growth factor (EGF) and fibroblast growth factor (FGF), platelet-derived somatomedin (PDGF) has all showed unstability, promptly be easy to inactivation at normal temperatures with in the water-bearing media, meet difficulty thereby cause in actual applications.The inventor finds utilizing the human fibroblastic growth factor (hFGF-2) produced with the DNA recombinant technique or its analog to prepare in the research process of local topical preparation that remedy for external use and preparation FGF-2 are the primary activity composition or cosmetic composition; in conventional carrier and excipient, add one or more sulfated polysaccharide class materials and be selected from Polyethylene Glycol; the material of polyacrylic acid and hydroxypropyl cellulose etc. is as stabilizing agent or activity protecting agent; can improve the stability of FGF-2 greatly; make the half life significant prolongation of this reactive protein in water-bearing media or gel, and have preferably anti-low pH ability and temperature tolerance preferably.
Therefore, an object of the present invention is to provide the composition for external application that contains the cell growth factor polypeptide, said composition contains at least a cell growth factor as active component, the stabilizing agent of at least a said active polypeptide, and acceptable substrate or excipient on the external preparation for skin.
According to one embodiment of the invention, wherein said cell growth factor is selected from fibroblast growth factor, epidermal growth factor, insulin like growth factor, platelet-derived somatomedin, and nerve growth factor and brain derived nerve growth factor.According to a preferred embodiment of the invention, wherein said cell growth factor is fibroblast growth factor and/or epidermal growth factor or their analog, and said cell growth factor can be extract from natural origin or produce with the DNA recombinant technique.
According to a preferred embodiment of the invention, wherein said substrate is the aqueous gel substrate that contains water solublity wetting agent, hydrophilic gel and pH regulator agent.According to this embodiment of the present invention, wherein said water solublity wetting agent component is selected from propylene glycol, 1,3-butanediol, glycerol, glycerol glycol, hyaluronic acid and sodium salt thereof or its cross-linked ester or by it isolating macromole hyaluronic acid element, or chitosan; Said hydrophilic gel is selected from carboxymethyl cellulose, hydroxypropyl cellulose, methylcellulose, polyvinylpyrrolidone, gelatin, xanthan gum, silicon cave natural gum, guar gum and alginic acid and sodium salt thereof.
According to one embodiment of the invention, wherein said reactive protein stabilizing agent is optional from sulfated polysaccharide for example carageen polysaccharide, heparin, heparin sulfate, dextran sulfate, sulphuric acid mannan, polyphosphoric acid pentosan, sulphuric acid ring mush, CSSO3, methylol aminopolysaccharide, hydroxy methocel, sucrose octasulfate and polyglycine, Polyethylene Glycol and polypropylene glycol.
According to this embodiment of the present invention, the wherein said content that is added in the cell growth factor in the water-setting gelatinous matrix is 0.1-1000ppm (weight), is preferably 1-100ppm; The content of water solublity wetting agent is 0.5-30% (weight): be preferably about 5-20% (weight); The content of hydrophilic gel is about 0.05-20% (weight), is preferably about 0.1-5% (weight); And the active polypeptide stabiliser content in the water-setting gum base is about 0.1-1000ppm, better is about 1-100ppm.
According to another embodiment of the invention, wherein said substrate is the Emulsion of being made by water, water solublity wetting agent, lipid and emulsifying agent.Wherein said emulsifying agent can be the lipophilic emulsifier of the Isosorbide Dinitrate of, two or the triglyceride that are selected from the saturated or unsaturated fatty acid of long-chain, saturated or unsaturated fatty acid; Be selected from phosphatidyl glycerol diacyl ester, the phospholipid of phosphatidylcholine diacyl ester, lecithin, phosphatidylcholine two myristoyl esters, phosphatidyl glycerol two myristoyl esters and be selected from the monostearate of polyethenoxy sorbitan, the amphoteric ion type emulsifying agent of monoleate.
According to the present invention, can add the free radical scavenger that one or more are selected from a-tocopherol, ascorbic acid, glutathion or derivatives thereof in the said aqueous gel type composition for external application that contains cell growth factor; One or more are selected from the vitamin of vitamin A, ascorbic acid, vitamin B, biotin, pantothenic acid, vitamin D, vitamin E; One or more are selected from methyl hydroxybenzoate, ethyl ester, propyl ester and butyl ester, and the waterborne-type preservation of phenoxypropanol.Can also contain the anti-wrinkle of skin that is selected from N-acetyl-L-cysteine and derivant thereof in addition forms agent and is selected from salicylic acid and the keratolytic of derivant, and the lubricant that is selected from polymethyl acid glyceride and derivant thereof, and the skin penetrant that is selected from lauric soap and dimethyl sulfoxine.
According to one embodiment of the invention, wherein can in said aqueous gel, add appropriate amount oleaginous base and emulsifying agent, make Emulsion according to a conventional method.
According to another embodiment of the present invention, wherein can utilize the combination of above-mentioned suitable composition or composition, make high sticking high gel or ointment according to a conventional method.
According to another embodiment of the present invention, wherein can utilize the combination of above-mentioned suitable composition or composition, make according to a conventional method cell growth factor is enclosed in liposome composition in the liposome.
According to another embodiment of the present invention, wherein can utilize the combination of above-mentioned proper composition or composition, make pre-adding according to a conventional method or use before the interim cell growth factor polypeptide that adds, contain the skin care liquid of one or more skin protectant in addition.
According to this embodiment of the present invention, wherein said skin protectant comprises but is not only limited to glycerol, hyaluronic acid, vitamin E, lecithin, amino acid complex, natural plants or animal extracts and native protein or polysaccharide hydrolysis thing.
The present invention further provides the method for preparing the aqueous gel type skin care compositions that contains cell growth factor, this method comprises the freeze-dried product for preparing the cell growth factor of extracting from natural origin or produce with the DNA recombinant technique respectively, with by the water solublity wetting agent, hydrophilic gel, the aqueous gel substrate that acceptable auxiliary element is formed on reactive protein stabilizing agent and other external preparation for skin, and under proper temperature that does not contain the biologic activity of destroying growth factor activity protein and pH condition, add said cell growth factor and fully mixing it.
According to a preferred embodiment of the invention, wherein the freeze-dried preparation of said cell growth factor is joined in the said aqueous gel substrate before use temporarily.
The present invention relates to comprise the aqueous gel type composition for external application of cell growth factor, said composition is by being selected from fibroblast growth factor, epidermal growth factor, insulin like growth factor, platelet-derived somatomedin, nerve growth factor, one or more active polypeptide of brain derived nerve growth factor and aqueous gel substrate are formed, wherein said cell growth factor can be when producing said composition for external application, joins in the said aqueous gel substrate under temperature that is unlikely to biologically active polypeptides is damaged or makes it inactivation and pH condition and uniform mixing with it; Perhaps also can prepare and pack the aqueous gel substrate of skin care compositions of the present invention and the freeze-dried preparation of cell growth factor respectively, join the freeze-dried powder of cytokine in the aqueous gel substrate according to the ratio of regulation before using temporarily and fully mixing it.
According to aqueous gel composition for external application of the present invention, wherein cell growth factor better is fibroblast growth factor and/or epidermal growth factor, and fibroblast growth factor-2 (FGF-2) preferably.Said FGF-2 can prepare by natural origin or with the DNA recombinant technique.
According to composition for external application of the present invention, wherein the water solublity wetting agent as one of hydrogel matrix composition can be the glycerol or derivatives thereof, for example propoxylated glycerol and ethoxylated glycerol, perhaps can be propylene glycol, ethylene glycol, polyvinylpyrrolidone, hyaluronic acid or its high molecular weight component, for example the hyaluronan of molecular weight more than 30kD (Hyalectin, HAC).Hyaluronic acid is as skin moisturizing regulator commonly used in the Cosmetic Manufacture, owing to be the one group of mixture that the heterogeneity molecular weight is arranged that extracts from natural origin, wherein molecular weight has the stronger anaphylaxis that causes less than the component of 30kD to skin, so the wetting agent that preferred use is made up of glycerol and hyaluronan in aqueous gel compositions of the present invention.Experiment shows, this wetting agent has fabulous hygroscopicity and releases moist, but the i.e. moisture content in its absorbing environmental under the environment of higher temperature, and discharge moisture content at the next skin that can promote of the environment of big humidity, thereby make local skin keep suitable humidity, promptly can promote the comfort of skin, help the abundant reservation of EGF in the present composition and FGF again and bring into play its biologic activity.Can be according to United States Patent (USP) 5,166, the method described in 331 is by hyaluronic acid preparation and purification hyaluronan.
According to the aqueous gel type skin care compositions that contains cell growth factor of the present invention, wherein the content of water solublity wetting agent account for composition total weight at about 0.1%-40%.Be preferably 1%-30%, preferably account for 5%-20%.
The aqueous gels that is used for the present composition can be cellulose ether, polyvinylpyrrolidone, polyvinyl alcohol, collagen hydrolysate, silicone natural gum, gelatin or xanthan gum of being selected from hydroxy methocel, hydroxyethyl-cellulose, methylcellulose and hydroxypropyl cellulose and composition thereof.Other aqueous gels that are suitable for are chain alkyl acrylate, for example better are the octadecyl acrylic acid methyl ester .s.Yet from helping protecting the angle of the biologically active polypeptides that will add the present composition, better being to use with the hydroxypropyl cellulose is the cellulose ether of representative and the mixture of collagen hydrolysate.The content of aqueous gels generally accounts for the 0.01%-10% of composition weight in the present composition, is preferably 0.1-3%, is preferably 0.5%-1%.
Under the situation for preparing the composition for external application that is added with cell growth factor in advance, the viscosity of aqueous gels better is about 400 to 4000Cps in the present composition.On the contrary, under the situation of the composition for external application of interim interpolation cell growth factor dried frozen aquatic products, aqueous gels viscosity better is about 200-1000Cps in the present composition before preparation is used.
As previously mentioned, because polypeptide cytokineses such as EGF and FGF are all relative unstable in room temperature and aqueous solution, be subjected to various Effect of Environmental and the degeneration inactivation than being easier to, therefore when preparation the present invention contains the composition for external application of cell growth factor, a primary aspect is to keep the stability of these biologic activity peptides in water-bearing media as much as possible, prolongs its activity and holds time.For this purpose, we use this laboratory with DNA recombinant technique preparation have the active polypeptide of human fibroblastic growth factor and its analog primary activity material as composition for external application of the present invention, and utilize the various protein stabilizing agent that is added in the aqueous gel substrate to carry out lot of experiments.Found that, particularly with the people of this prepared in laboratory recombinate FGF or its analog (rhFGF-Arg
78, Arg
96. be FGF-2m) under the situation as active component, in gel-type vehicle of the present invention (glycerol adds the 0.9%NaCl solution of CMC), add be selected from Polyethylene Glycol, hydroxypropyl cellulose, sulfated polysaccharide and glutathion one or more materials as stabilizing agent, can make in this skin care compositions rhFGF-2 or rhFGF-2m improve nearly 10% (seeing EXPERIMENTAL EXAMPLE) in 6 months stability of room temperature preservation.The wherein said sulfated polysaccharide class material that is suitable for use as stabilizing agent comprises salt, polyglycine and the trimethyl glycine of PEG400, carageen polysaccharide, heparin, heparin sulfate, dextran sulfate, many sulphuric acid pentosan, sulphuric acid mannan, sulphuric acid cyclodextrin, methylol chitin, sucrose octasulfate.
Can prepare above-mentioned aqueous gel skin care compositions according to conventional method well known to those skilled in the art.
Though one object of the present invention mainly relates to contain FGF and/or EGF and the aqueous gel compositions of other cell growth factor that may add, the present invention has more than the compositions that is limited to the aqueous gel dosage form.It will be appreciated by those skilled in the art that: at conventional lipid skin moistening material low gel content, that add appropriate amount in the low viscous water-bearing media, for example glyceride, plant or mineral oil, alkenyl ester, ethoxylation lipidol and add suitable emulsifying agent or have the phospholipid of emulsification function or polymer-modified, for example non-ionic polyacrylamide can be made Emulsion or liposome composition with compositions of the present invention.
Emulsion, particularly oil-in-water emulsion are the systems that the most generally uses that so far functional skin care formulation is used for skin.Therefore, can use conventional method that compositions of the present invention is made Emulsion.In order to help being included in the dispersion and the absorption of Emulsion aqueous phase active polypeptide, better use mineral oil, for example silicone oil uses the isotonic sodium chlorrde solution that is dissolved with Polyethylene Glycol and emulsion and polypropylene cellulose as water as oil phase, and uses (C
10-22) alkyl acrylate, for example lauryl acrylate or stearyl acrylate acid esters are as primary emulsion and surfactant.In addition, can also use suitable alkali nertralizer or citrate buffer that the pH value of gained Emulsion is maintained in the scope of about neutrality or meta-alkalescence.
Can before the preparation emulsion, in above-mentioned host material, add FGF-2 and or the EGF polypeptide, and active polypeptide protective agent or stabilizing agent add the pH regulator agent in case of necessity.Perhaps also can be after making Emulsion, adding active polypeptide and stabilizing agent or protective agent before using, and with above-mentioned substrate mixing after be coated on skin surface.
The emulsifying agent that is suitable for can be the lipophilic emulsifier of the Isosorbide Dinitrate of, two or the triglyceride that are selected from the saturated or unsaturated fatty acid of long-chain, saturated or unsaturated fatty acid; Be selected from the phospholipid of phosphatidyl glycerol diacyl ester, phosphatidylcholine diacyl ester, lecithin, phosphatidylcholine two myristinates, phosphatidyl glycerol two myristinates; And be selected from the monostearate of polyethenoxy sorbitan, the amphoteric ion type emulsifying agent of monoleate.
According to another embodiment of the invention, can also be by thin layer hydration known in the art, anti-phase evaporation (for example referring to Szoka, F.et al., Proc.Natl.Acad.Sci, USA, 75:4194-4197,1978), and solvent injection method, compositions of the present invention is made the high-viscosity gel or the paste composition for external application of FGF-2/ or EGF/ liposome.In FGF-2/ liposome of the present invention, the content of neutral phospholipid and electronegative phospholipid accounts for the 20-50% of gross weight respectively.Employed neutral phospholipid can be selected from the phospholipid of or chemosynthesis isolating from natural origin with known method, for example can be by the phosphatidyl glycerol ester or the phosphatidyl inositide that extract in the yolk.In addition, in lipid components, can add cholesterol, so as to the stability of raising liposome bilayer, thus FGF that substantially extension body is outer (or in body) discharges and/or the half life of EGF.Moreover, in this liposome composition, can also contain other and be used to improve liposome stability and stability and the favourable composition of release characteristic, for example alpha-tocopherol of alpha-tocopherol or polyethoxylated of active polypeptide.
In order to prepare FGF-2/ lipidosome gel compositions of the present invention, vesicle can be generated fat and be dissolved in the suitable organic solvent, and dry to form thin lipid film under vacuum.Under strong agitation, make this film water and about 30 minutes then, to obtain vesicle.This vesicle is scattered in the aforementioned gel-type vehicle, so that the FGF-2 liposome accounts for the 5-20% of composition total weight.The hydration that above-mentioned vesicle forms fat contains more fortunately in the low electric conductivity water-bearing media of zwitterionic compound and carries out.The liposome aqueous gel compositions that so obtains is gelatinous, and has low relatively lipid concentration.
In addition, also can at first the ampholyte chemical compound that is not in isoelectric point, IP be joined in the lipid film to form liposome, the pH with water-bearing media is transferred to the isoelectric point, IP of this medium to reach required gel state then.FGF-2 can be dissolved in suitable concentration in the preparation and be used for forming in the water-bearing media of liposome composition.The suspension of making by this way comprises microencapsulated encapsulate, liposome absorption and free F GF-2 or FGF-2m.As mentioned above, can after liposome is made, FGF-2 be added in the established liposome, to produce the FGF-2/ liposome composition that has only adsorbed FGF-2.
The fluidic FGF-2 of the containing liposome composition that makes as stated above can be mixed to make the paste composition of higher liposome concentration with the neutral fat plastid of sky, perhaps there is the aqueous gel compositions of viscosity higher to mix with aforementioned the said FGF-2 of containing liposome composition, to obtain the paste composition of low lipid concentration.The FGF-2/ liposome composition of so making has the high viscosity of about 1000-10000Cps.
The invention provides and contain cell growth factor; the composition for external application of fibroblast growth factor-2 and/or epidermal growth factor particularly; be characterised in that said composition contains on the cosmetics and the pharmaceutically FGF-2 of effective dose and/or protein protectant or the stabilizing agent of EGF, and said composition can be aqueous gel or Emulsion or liposome composition form.According to compositions of the present invention, wherein bigger biologic activity can be kept and keep to active component on the one hand, and infiltrate skin and bring into play its inherent biological action; Said composition also has advantages of good skin sensation and persistence characteristic on the other hand, and good wettability, permeability and absorbability.
Using FGF-2; particularly use the FGF-2 analog (FGF-2m) (referring to the patent application № .96114279.0 that awaits the reply jointly) of this Laboratory Production to do under the situation of active component of composition for external application of the present invention; because we utilize side-directed mutagenesis that the 78th and 96 cysteine that is exposed to molecular surface in the FGF-2 aminoacid sequence three-D space structure changed over arginine rather than the serine that has amino group; thereby more help said amino group and can add in the compositions as the formation of the oh group in protectant peg molecule covalent bond; so as to preventing the FGF-2 molecule aggregation, thereby improved the stability of reactive protein greatly.In addition, because composition for external application of the present invention mainly is not contain lipid or only contain the aqueous gel form of seldom measuring lipid, so no matter wherein contain or do not contain cutaneous permeable agent, all can make said reactive protein be able to absorption maximum, and have the characteristic that postpones release at agents area in the part.
Also answer lay special stress on to be pointed out that at last, though in order to keep the biologic activity of cell growth factor to greatest extent, skin protection substrate of the present invention and cell growth factor polypeptide can be separated to pack also to mix also by user before use temporarily and use it in the time limit at the appointed time, but also can in the substrate of the present composition, directly sneak into these peptide materials in process of production fully, its biologic activity obviously be reduced and be unlikely.
Below by implementing the present invention is described for example further, but these embodiment limit the scope of the invention by any way.
EXPERIMENTAL EXAMPLE
In the present embodiment, use the l cell of cultivating as target cell, with
3The H-thymidine (
3H-TdR) method of mixing detect in composition for external application of the present invention, add heparin sulfate or dextran sulfate and Polyethylene Glycol to substrate in the influence of biologic activity of contained hbFGF-2m.
1. the preparation of sample and storage: the aqueous gel substrate that is used for this experiment according to prescription described in the embodiment 1 and compound method preparation.The amount of these substrate with every pipe 4ml is added on respectively in 4 groups of 12 sterile test tube (20ml volume).The 1st group of gel adds 10mM (1ml) PBS as negative control; The 2nd group of dextran sulfate solution that adds 0.1ug/ml; The 3rd group of Polyethylene Glycol (each 0.5ml) that adds 1ug/ml heparin sulfate and 0.2ug/ml; The 4th group adds the gel-type vehicle that the 1ug/ml hydroxypropyl cellulose that is dissolved in 10mM PBS (1ml) obtains viscosity higher.In above-mentioned 2,3,4 groups of samples, add hFGF-2m with the heavy dose of of 1ug/ml respectively then.Use be added with same amount hFGF-2m but do not add stabilizing agent gel-type vehicle (with the 1st group than the low viscosity gel-type vehicle) as positive control, and be decided to be the 5th group.After preparation is finished above-mentioned all samples being contained in aseptic vial with cover, to be built in room temperature (20-25 ℃) under placement 6 months standby.
2. preparation of target cell and detection: briefly, at first with about 10
6Individual BALB/c3T3 cell (being provided by institute of Materia Medica,Chinese Academy of Medical Sciences) is inoculated in 3ml and contains in the DMEM culture medium of 10% hyclone.In 37 ℃ at 5%CO
2Cultivate in the incubator after 24 hours,, make the final concentration of serum become 1% with fresh DMEM culture medium dilution culture.Continue to cultivate after 2 days, in culture, add and as above prepare and store 6 months test specimen and control sample (2ml/10
5Individual cell).And add
3H-TdR (final concentration is 2uCi/ml).37 ℃ are continued insulation after 24 hours, wash cell 3 times with cold saline.Centrifugal back adds 10% trichloroacetic acid with precipitating proteins in the cell precipitation thing.Wash 2 times with normal saline once more, and the adding alcohol-ether is washed once.Be added on mensuration radiation counting in the 4ml scintillation vial with getting 0.1ml behind the formic acid digestion precipitate.
Calculate FGF-2m to the synthetic stimulation index of 3T3 cell DNA and obtain result as shown in table 1 by following formula.The mean+SD of data represented three mensuration shown in the table.
The stable group of table 1 FGF in aqueous gel compositions handled cell
3H-TdR incorporation (CPM) stimulation index p value 1 negative control (no FGF) 16,065 1.00-2 gels+heparin+FGF 24,576 1.52＜0.053 gel+heparin+25,387 1.58＜0.05
Polyethylene Glycol+FGF4 high-viscosity gel+FGF 23,875 1.48＜0.055 gels+FGF 23,064 1.43＜0.05
(positive control)
From the result shown in the last table as can be seen, have the polypeptide (FGF-2m) of fibroblastic growth stimulating activity in the skin care compositions of the present invention, in aqueous gel substrate, after storing 6 months under the room temperature, still remain with higher biologic activity.In addition, in compositions of the present invention, add the material that PEG400, emulsion and polypropylene cellulose and sulfated polysaccharide etc. have FGF-2 stabilisation function, can protect the biologic activity of this polypeptide effectively.In this experimental system, and do not add stabilizing agent or protectant sample is compared, add these stabilizing agents and can make protein active exceed about 11%.
Embodiment 1: contain aqueous gel and the preparation thereof of FGF-2m
Use conventional hybrid technology to mix following (A) aqueous gel substrate and (B) contain the aqueous solution of FGF-2 and stabilizing agent thereof:
Composition percentage by weight A. glycerol 20.0
PEG400 2.0
Hydroxypropyl cellulose 2.0
Methyl parahydroxybenzoate 0.2
Polymethyl glyceride 0.6B. reorganization FGF-2 10ppm
Dextran sulfate 0.05
Hyaluronan 0.05
Distilled water adds to 100.0
Above-mentioned raw materials A after 55 ℃ of dissolvings and fully mixing, is cooled to 40 ℃, adds the aqueous solution of raw material B and with the further mix homogeneously of agitator, the 0.1M NaOH solution that adds appropriate amount then is transferred to the pH of gained gel about 6.5.The aqueous gel that so makes has less viscosity, can keep the biologic activity of FGF-2m by stabilizing agent effectively.In addition, this gel has the advantages of good skin sensation when being applied to skin surface, and fabulous wettability and permeability are arranged.
Embodiment 2: the preparation of aqueous solution substrate and use
Use conventional hybrid technology to mix following component, be used as the aqueous solution substrate of skin lotion with preparation:
The composition percentage by weight
Glycerol 20.0
Dextran sulfate 0.02
Normal saline adds to 100.0
The so mixed aqueous solution that gets is preserved separately, extract cold-dry powder that (2ml) this aqueous solution in a small amount places the FGF-2 in another sterile chamber in order to dissolving not by user during use, treat to refill after the fully dissolving in the said aqueous solution fully mixing and dosage according to the rules and use as early as possible.Embodiment 3: the oil-in-water emulsion and the substrate preparation that contain FGF-2 use conventional mixing and emulsifying technology preparation to contain the emulsion composition of following ingredients:
Composition percentage by weight A. polyoxyethylene (20)
Arlacel-60 2.0
Hydrogenated lanolin 5.0
Squalene 10.0
Cera Flava 4.0
Glycerol 10.0
Silicone oil 0.5
Vitamin E 0.1
Propylene glycol 2.0
Polyethylene Glycol 0.5B. FGF-2 5ppm
Heparin sulfate 0.1
Hyaluronate sodium 0.05
Distilled water adds to 100.0
The oil phase substrate raw material A is heated to 75 ℃ of thawings, mixing and be cooled to 40 ℃ after add aqueous phase B solution, fully stir and be cooled to room temperature then.The emulsion that so makes has good stable, and with contact skin after rapid breakdown of emulsion and can impel the FGF-2 that is contained in aqueous phase to infiltrate skin as early as possible.This Emulsion also has good water retention property and scrubbing effect in addition.
Embodiment 4: contain oil-in-water emulsion and the preparation thereof of FGF-2
Use conventional mixing and emulsifying technology preparation to contain the emulsion composition of following ingredients:
Composition percentage by weight A. lecithin 4.0
Glycerol monostearate 3.0
Lanolin alcohol 3.0
Disodiumedetate 0.05
Glycerol 3.0
Carboxymethyl cellulose 0.2
Isopropyl myristate 5.0
Methyl parahydroxybenzoate 0.1
An amount of B. FGF-2 of citrate buffer 5ppm
CSSO3 0.1
Vitamin C 0.01
Distilled water adds to 100.0
Place 80 ℃ to melt down raw material A, stir companion's mixing and be cooled to 50 ℃.Further use ultrasonic emulsator emulsifying then, add the aqueous solution of raw material B simultaneously, obtain uniform cream sample preparation.Said preparation has viscosity higher, more helps keeping the biologic activity of FGF-2 in the presence of protective agents such as heparin.
Embodiment 5: contain the preparation of the liposome composition of FGF-2
With contain lecithality phosphatldylcholine/yolk phosphatidyl glycerol/cholesterol/alpha-tocopherol (1: 1: 0.5: dehydration lipid mixture 0.02 weight ratio), with the legal preparation liposome of conventional pellicular water.At first, the lipid material dissolution in chloroform/methanol (2: 1 weight ratios), and is poured into gained solution at the bottom of the garden in the flask.Form the thin layer lipid film behind the vacuum drying.On this film, pour the hydration buffer of 2.5% (weight/volume) glycine (a kind of zwitterionic compound) of 10 times of volume/weight into.Eddy current stirs down, and hydration obtains tremelloid liposome material after 1.5 hours.Can use the lipid and the aqueous solution of bactericidal device, filtration sterilization, this liposome vesicle material of preparation in sterilizing room is to reduce microbial contamination as much as possible.Use Brookfield DV-II viscometer, the average viscosity that records this liposome composition after adding 0.1%NaCL (weight) is 1.5 * 103Cps.
The concentration that wherein is used to form the interior contained FGF-2 of water-bearing media (above-mentioned buffer) of liposome composition can be decided according to application target and gel coating part, generally accounts for the 0.1-100ppm of total composition.Can when adding FGF-2, add protective agent or the stabilizing agent that is selected from Polyethylene Glycol, hydroxypropyl cellulose and sulfated polysaccharide in the lump.Can comprise that be wrapped, that be adsorbed and free F GF-2 in the formed liposome suspension.Also can form the back and add FGF-2 with suitable concentration at liposome.
The Liposomal formulation that so obtains can use separately, also can mix the back by proper proportion at the gel-type vehicle that makes with embodiment 1 and use.Said preparation can further keep the biologic activity of FGF-2 effectively, and can reach the purpose that delays to discharge active polypeptide in the part.
Claims (18)
1. the composition for external application that contains cell growth factor, said composition contain at least a cell growth factor polypeptide, the stabilizing agent of at least a said polypeptide, and acceptable substrate on the external preparation for skin.
2. according to the compositions of claim 1, wherein said cell growth factor polypeptide is selected from fibroblast growth factor, epithelical cell growth factor, insulin like growth factor, platelet-derived somatomedin and nerve growth factor and brain derived nerve growth factor polypeptide.
3. according to the compositions of claim 2, wherein said cell growth factor polypeptide is fibroblast growth factor-2 and epithelical cell growth factor.
4. according to any one compositions in the claim 1 to 3, wherein said cell growth factor polypeptide be extract from natural origin or produce with the DNA recombinant technique.
5. according to any one compositions in the claim 1 to 3, the stabilizing agent of wherein said cell growth factor polypeptide is selected from Polyethylene Glycol, POLYPROPYLENE GLYCOL, methylcellulose, hydroxypropyl cellulose, carboxymethyl cellulose, heparin, heparin sulfate, CSSO3, dermatan sulfate, methylol aminopolysaccharide, many sulphuric acid pentose, sulphuric acid mannan, dextran sulfate, carageen polysaccharide, sulphuric acid cyclodextrin, methylol chitin, hyaluronan, hyaluronic acid, sucrose octasulfate, polyglycine, trimethyl glycine and glutathion and half amic acid.
6. according to the compositions of claim 1, wherein said substrate is aqueous gel substrate.
7. according to the compositions of claim 6, wherein said aqueous gel substrate contains water-soluble fluidity wetting agent, hydrophilic gel and pH regulator agent.
8. according to the compositions of claim 7, wherein said water solublity wetting agent is selected from glycerol, glycerol glycol, propylene glycol, 1,3 butylene glycol, hyaluronic acid and sodium salt thereof or its cross-linked ester or by it isolating macromole hyaluronan, or chitosan; And wherein said hydrophilic gel is selected from hydroxy methocel, hydroxypropyl cellulose, methylcellulose, polyvinylpyrrolidine cave, gelatin, xanthan gum, silicone natural gum, guar gum and alginic acid and sodium salt thereof.
9. according to the compositions of claim 1, wherein said substrate is the aqueous solution that contains one or more emollient and polypeptide stabilizing agent.
10. according to the compositions of claim 1, wherein said substrate is oil-in-water type or water-in-oil emulsion.
11. according to the compositions of claim 1, wherein said substrate is liposome or its compositions.
12. according to any one compositions in claim 1 or 6 to 11, wherein said cell growth factor polypeptide is to add in the said substrate of preparation, or forms independent placement and interim adding the before using with its lyophilizing.
13. according to any one compositions in the claim 6 to 11, wherein said cell growth factor is fibroblast growth factor-2 and/or epidermal growth factor.
14. according to the compositions of claim 13, wherein said fibroblast growth factor and/or the content of epidermal growth factor in said compositions are about 1-100ppm.
15., also contain penetrating dose of one or more skins in the said substrate according to any one compositions in the claim 1 to 11.
16., also contain one or more vitamin in the said substrate according to any one compositions in the claim 1 to 11.
17., also have one or more antioxidants in the said substrate according to any one compositions in the claim 1 to 11.
18., also contain one or more free radical scavengers in the wherein said substrate according to any one compositions in the claim 1 to 11.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96114282 CN1160582A (en) | 1996-12-27 | 1996-12-27 | External-use composite containing cell growth factor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 96114282 CN1160582A (en) | 1996-12-27 | 1996-12-27 | External-use composite containing cell growth factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1160582A true CN1160582A (en) | 1997-10-01 |
Family
ID=5122048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 96114282 Pending CN1160582A (en) | 1996-12-27 | 1996-12-27 | External-use composite containing cell growth factor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1160582A (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306954C (en) * | 2001-12-20 | 2007-03-28 | 遗传和生物技术工程中心 | Use of a pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
| CN100352498C (en) * | 2005-09-30 | 2007-12-05 | 上海第二医科大学附属第九人民医院 | Three dimensional eye patch for treating eye wrinkles an its preparation method |
| CN100402086C (en) * | 2006-12-20 | 2008-07-16 | 张纲 | Basic fibroblast growth factor polylactic acid sustained-release nano-microsphere gel and preparation method thereof |
| CN101965357A (en) * | 2007-08-15 | 2011-02-02 | 特拉维夫大学拉莫特有限公司 | Polypeptides, matrices, hydrogels and methods of using same for tissue regeneration and repair |
| CN102020710A (en) * | 2010-09-03 | 2011-04-20 | 深圳市华生元基因工程发展有限公司 | Novel mutant EN-46 of human epidermal growth factor |
| CN102552091A (en) * | 2012-02-08 | 2012-07-11 | 梁杰 | Liquid eyeliner with effect of promoting eyelash growth |
| CN103203021A (en) * | 2013-01-31 | 2013-07-17 | 何荫良 | Hair pilatory and preparation method thereof |
| CN103479567A (en) * | 2013-09-29 | 2014-01-01 | 广州市娇兰化妆品有限公司 | Epidermal growth factor complex lipidosome, and preparation method and application of lipidosome |
| EP2391209A4 (en) * | 2009-01-27 | 2014-03-26 | Teleflex Medical Inc | EXPECTORING ASPIRATION AND DISSOLUTION SOLUTION FOR ENDOTRACHEAL PROBE AND TRACHEOSTOMY PROBE |
| CN103720642A (en) * | 2012-10-16 | 2014-04-16 | 北京泰德制药股份有限公司 | Bioprotein-containing solution for external use and preparation method thereof |
| CN104042449A (en) * | 2014-05-26 | 2014-09-17 | 诺斯贝尔(中山)无纺日化有限公司 | High-temperature stable hydrogel mask |
| CN105078784A (en) * | 2014-04-25 | 2015-11-25 | 张文炜 | Peptide skin care product and preparation method thereof |
| CN105708778A (en) * | 2016-02-02 | 2016-06-29 | 广州赛莱拉干细胞科技股份有限公司 | Skin care composition, skin cream and preparation method thereof of skin cream |
| CN106309368A (en) * | 2015-06-24 | 2017-01-11 | 陕西艾美雅生物科技有限公司 | Composite bioactive factor liposome and preparation method thereof |
| CN106491486A (en) * | 2016-10-26 | 2017-03-15 | 武汉汉密顿生物科技股份有限公司 | A kind of liposome turbid liquor containing the derivative liquid of cord blood stem cell and preparation method thereof and the application in cosmetics |
| CN107405279A (en) * | 2015-03-27 | 2017-11-28 | 株式会社科拉途日本 | cosmetics containing hydrogel |
| CN108014036A (en) * | 2016-11-04 | 2018-05-11 | 无锡法瑞雅生物细胞科学有限公司 | A kind of peel off pack and preparation method thereof |
| CN110201147A (en) * | 2019-05-23 | 2019-09-06 | 中山市粤美医疗生物科技有限公司 | A kind of composition and preparation method thereof comprising peptide |
| CN110237236A (en) * | 2018-07-25 | 2019-09-17 | 贝妮芙生物研究室株式会社 | For treating the skin ointments of skin of labium minus |
| KR20190116693A (en) * | 2018-04-05 | 2019-10-15 | 주식회사 엔씨엘바이오 | Cosmetic composition for improving skin condition comprising human epidermal growth factor, peptides and functional materials |
| CN112138144A (en) * | 2019-06-28 | 2020-12-29 | 杭州生物医药创新研究中心 | Liposome containing active biological factor and preparation method thereof |
| CN112261871A (en) * | 2018-07-28 | 2021-01-22 | 韩国外泌体生技有限公司 | Methods for lyophilizing exosomes |
| CN112739325A (en) * | 2018-06-29 | 2021-04-30 | 株式会社日本触媒 | Gel-in-oil type emulsion and transdermal absorbent |
| CN114306242A (en) * | 2021-12-29 | 2022-04-12 | 广州佰斯伦医疗器械有限公司 | Liposome particle containing growth factor nanogel and preparation method and application thereof |
| US11529306B2 (en) | 2018-07-30 | 2022-12-20 | Exocobio Inc. | Lyophilized formulation of stem cell-derived exosomes and anti-inflammatory composition including the same as active ingredient |
| US11730695B2 (en) | 2018-05-31 | 2023-08-22 | Exocobio Inc. | Composition for alleviating facial redness, comprising stem cell-derived exosomes as active ingredient |
| CN116889545A (en) * | 2023-06-27 | 2023-10-17 | 上海腾瑞制药股份有限公司 | A kind of recombinant human acidic fibroblast growth factor gel and its preparation process |
-
1996
- 1996-12-27 CN CN 96114282 patent/CN1160582A/en active Pending
Cited By (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1306954C (en) * | 2001-12-20 | 2007-03-28 | 遗传和生物技术工程中心 | Use of a pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention |
| CN100352498C (en) * | 2005-09-30 | 2007-12-05 | 上海第二医科大学附属第九人民医院 | Three dimensional eye patch for treating eye wrinkles an its preparation method |
| CN100402086C (en) * | 2006-12-20 | 2008-07-16 | 张纲 | Basic fibroblast growth factor polylactic acid sustained-release nano-microsphere gel and preparation method thereof |
| CN101965357A (en) * | 2007-08-15 | 2011-02-02 | 特拉维夫大学拉莫特有限公司 | Polypeptides, matrices, hydrogels and methods of using same for tissue regeneration and repair |
| CN101965357B (en) * | 2007-08-15 | 2014-11-05 | 特拉维夫大学拉莫特有限公司 | Polypeptides, matrices, hydrogels and methods of using them for tissue regeneration and repair |
| EP2391209A4 (en) * | 2009-01-27 | 2014-03-26 | Teleflex Medical Inc | EXPECTORING ASPIRATION AND DISSOLUTION SOLUTION FOR ENDOTRACHEAL PROBE AND TRACHEOSTOMY PROBE |
| CN102020710A (en) * | 2010-09-03 | 2011-04-20 | 深圳市华生元基因工程发展有限公司 | Novel mutant EN-46 of human epidermal growth factor |
| CN102020710B (en) * | 2010-09-03 | 2012-09-05 | 深圳市华生元基因工程发展有限公司 | Novel mutant EN-46 of human epidermal growth factor |
| CN102552091A (en) * | 2012-02-08 | 2012-07-11 | 梁杰 | Liquid eyeliner with effect of promoting eyelash growth |
| CN103720642A (en) * | 2012-10-16 | 2014-04-16 | 北京泰德制药股份有限公司 | Bioprotein-containing solution for external use and preparation method thereof |
| CN103203021A (en) * | 2013-01-31 | 2013-07-17 | 何荫良 | Hair pilatory and preparation method thereof |
| CN103479567A (en) * | 2013-09-29 | 2014-01-01 | 广州市娇兰化妆品有限公司 | Epidermal growth factor complex lipidosome, and preparation method and application of lipidosome |
| CN103479567B (en) * | 2013-09-29 | 2016-01-20 | 广州市娇兰化妆品有限公司 | Epidermal growth factor complex liposome and its preparation method and application |
| CN105078784B (en) * | 2014-04-25 | 2018-07-20 | 张文炜 | Peptides skin care item and preparation method thereof |
| CN105078784A (en) * | 2014-04-25 | 2015-11-25 | 张文炜 | Peptide skin care product and preparation method thereof |
| CN104042449A (en) * | 2014-05-26 | 2014-09-17 | 诺斯贝尔(中山)无纺日化有限公司 | High-temperature stable hydrogel mask |
| CN104042449B (en) * | 2014-05-26 | 2015-09-16 | 诺斯贝尔(中山)无纺日化有限公司 | A kind of hydrogel mask sheet of high-temperature stable |
| CN107405279A (en) * | 2015-03-27 | 2017-11-28 | 株式会社科拉途日本 | cosmetics containing hydrogel |
| CN106309368A (en) * | 2015-06-24 | 2017-01-11 | 陕西艾美雅生物科技有限公司 | Composite bioactive factor liposome and preparation method thereof |
| CN105708778A (en) * | 2016-02-02 | 2016-06-29 | 广州赛莱拉干细胞科技股份有限公司 | Skin care composition, skin cream and preparation method thereof of skin cream |
| CN105708778B (en) * | 2016-02-02 | 2018-09-21 | 广州赛莱拉干细胞科技股份有限公司 | A kind of skin care compositions and a kind of face cream and preparation method thereof |
| CN106491486A (en) * | 2016-10-26 | 2017-03-15 | 武汉汉密顿生物科技股份有限公司 | A kind of liposome turbid liquor containing the derivative liquid of cord blood stem cell and preparation method thereof and the application in cosmetics |
| CN108014036B (en) * | 2016-11-04 | 2020-10-09 | 无锡法瑞雅生物细胞科学有限公司 | Peel-off facial mask and preparation method thereof |
| CN108014036A (en) * | 2016-11-04 | 2018-05-11 | 无锡法瑞雅生物细胞科学有限公司 | A kind of peel off pack and preparation method thereof |
| KR20190116693A (en) * | 2018-04-05 | 2019-10-15 | 주식회사 엔씨엘바이오 | Cosmetic composition for improving skin condition comprising human epidermal growth factor, peptides and functional materials |
| US11730695B2 (en) | 2018-05-31 | 2023-08-22 | Exocobio Inc. | Composition for alleviating facial redness, comprising stem cell-derived exosomes as active ingredient |
| CN112739325A (en) * | 2018-06-29 | 2021-04-30 | 株式会社日本触媒 | Gel-in-oil type emulsion and transdermal absorbent |
| CN110237236A (en) * | 2018-07-25 | 2019-09-17 | 贝妮芙生物研究室株式会社 | For treating the skin ointments of skin of labium minus |
| CN112261871A (en) * | 2018-07-28 | 2021-01-22 | 韩国外泌体生技有限公司 | Methods for lyophilizing exosomes |
| CN112261871B (en) * | 2018-07-28 | 2022-05-17 | 韩国外泌体生技有限公司 | Method for lyophilizing exosomes |
| US11337419B2 (en) | 2018-07-28 | 2022-05-24 | Exocobio Inc. | Method for lyophilizing exosome |
| US11529306B2 (en) | 2018-07-30 | 2022-12-20 | Exocobio Inc. | Lyophilized formulation of stem cell-derived exosomes and anti-inflammatory composition including the same as active ingredient |
| CN110201147A (en) * | 2019-05-23 | 2019-09-06 | 中山市粤美医疗生物科技有限公司 | A kind of composition and preparation method thereof comprising peptide |
| CN112138144B (en) * | 2019-06-28 | 2023-02-24 | 杭州生物医药创新研究中心 | Liposome containing active biological factor and preparation method thereof |
| CN112138144A (en) * | 2019-06-28 | 2020-12-29 | 杭州生物医药创新研究中心 | Liposome containing active biological factor and preparation method thereof |
| CN114306242A (en) * | 2021-12-29 | 2022-04-12 | 广州佰斯伦医疗器械有限公司 | Liposome particle containing growth factor nanogel and preparation method and application thereof |
| CN116889545A (en) * | 2023-06-27 | 2023-10-17 | 上海腾瑞制药股份有限公司 | A kind of recombinant human acidic fibroblast growth factor gel and its preparation process |
| CN116889545B (en) * | 2023-06-27 | 2023-12-29 | 上海腾瑞制药股份有限公司 | A kind of recombinant human acidic fibroblast growth factor gel and its preparation process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1160582A (en) | External-use composite containing cell growth factor | |
| US6096324A (en) | Methods of delivering materials into the skin, and compositions used therein | |
| US20030077235A1 (en) | Topical formulations comprising ceramic hydroxyapatite particles | |
| CN115554187B (en) | A mussel mucin skin repair emulsion that can be sterilized by moist heat and its preparation method | |
| JPH0661262B2 (en) | Method of stimulating cell proliferation | |
| CN113301910A (en) | Skin rejuvenation and healing mixtures of peptide components and uses thereof | |
| KR101339423B1 (en) | cosmetic composition having collagen derived from fishes and manufacturing method thereof | |
| KR20090014150A (en) | Use as synthetic peptides and cosmetic or dermatological compositions useful for the treatment of skin | |
| KR20190011054A (en) | Skin external application composition for promoting wound healing or cosmetic composition for improving wrinkle comprising oil of Tenebrio molitor mealworm | |
| JP5144690B2 (en) | Pharmaceutical and cosmetic compositions containing PLGF-1 | |
| CN111420023B (en) | Complex containing type I collagen and hyaluronic acid, preparation and application | |
| JP2006348035A (en) | Preparation suitable for external application | |
| CN103479567A (en) | Epidermal growth factor complex lipidosome, and preparation method and application of lipidosome | |
| JPH11502235A (en) | Dictiotail-derived extract, method for preparing the same and composition containing the extract | |
| Chen et al. | Novel topical drug delivery systems and their potential use in scars treatment. | |
| DE60007973T2 (en) | MATRIX PROTEIN COMPOSITIONS FOR Grafting In Non-Mineralized Tissues | |
| WO1990003797A1 (en) | Stabilized composition based on growth factors of the family fgf and on dextrane sulfate, and its applications | |
| Chen et al. | Wound healing effects of cactus extracts on second degree superficial burned mice | |
| JPH10251132A (en) | Method for transportation of material into skin and composition used for the same | |
| RU2784355C1 (en) | Recombinant angiogenin in cosmetic and pharmaceutical compositions | |
| US20050260275A1 (en) | Encapsulated peptide copper complexes and compositions and methods related thereto | |
| RU2196569C1 (en) | Method of preparing ointment "apilar-g" eliciting anti-inflammatory effect | |
| RU2401099C2 (en) | Skin treatment composition containing human growth hormones as active ingredient | |
| HK1078469B (en) | Pharmaceutical and cosmetic compositions comprising plgf-1 | |
| AU7224200A (en) | Methods of delivering materials into the skin and compositions used therein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |